

CERTIFICATE

Survey of 19 May 2023

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr. Martin Spacek, PhD.

Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 28 June 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 19 May 2023

You have participated in the External Quality Assessment with the following analysis

Haemostasis 23 - Rivaroxaban (503):

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Participant:
2430
MUDr. Martin Spacek, PhD.
Vseobecna fakultni nemocnice v Praze
Centralni hematologicke laboratore ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 28 June 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)